Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® ...
GlobalData on MSN19h
Palforzia’s peanut allergy treatment use in Europe expanded to toddlersThe EC has approved the extension of Stallergenes Greer’s Palforzia for the treatment of peanut allergy in toddlers.
The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
As the new year sparks a wave of weight loss resolutions and millions turn to weight loss medications, rising costs and the ...
Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...
We looked at data released by the Food and Drug Administration in 2013 on the ... When we shared our results with the FDA and asked for comment, the agency reiterated its recommendation that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback